PH III: AZIMILIDE LONG TERM TREATMENT

PH III：阿齐利利长期治疗

• 批准号: 6302923
• 负责人: TRISTRAM D BAHNSON
• 金额: $ 4.09万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2000-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6302923
• 关键词: antiarrhythmic agent; atrial fibrillation; clinical research; heart disorder chemotherapy; human old age (65+); human subject; human therapy evaluation; longitudinal human study; tachycardia

Atrial fibrillation is the most common cause of clinically significant sustained tachycardia and occurs in up to 12% of individuals that are over age 75. Incidence increases with each decade of life. Furthermore, atrial fibrillation is responsible for up to 1/3 of thromboembolic strokes. The selection of available antiarrhythmic drugs and their efficacy is limited. Accordingly, there is an important need for the development of new antiarrhythmic agents that are safe in patients with structural heart disease and are absence of significant negative chronotropic effects. One such drug is Azimilide dihydrochloride, a class III antiarrhythmic agent with very weak bradycardic effects at test doses. This study is to test the long-term safety and efficacy of this new antiarrhythmic drug.

心房颤动是临床上显著持续性心动过速的最常见原因，75岁以上的人中有高达12%的人会发生房颤。发病率随着生命每十年的增长而增加。此外，高达三分之一的血栓栓塞性中风是由房颤引起的。现有的抗心律失常药物的选择和疗效有限。因此，有必要开发新的抗心律失常药物，这些药物对结构性心脏病患者是安全的，并且没有显著的负变时作用。其中一种药物是盐酸阿齐米特，这是一种III类抗心律失常药物，在测试剂量下具有非常微弱的心动过缓作用。这项研究旨在测试这种新型抗心律失常药物的长期安全性和有效性。